Search Within

Neeta Pandit-Taskar

Formats
  1. Meeting Abstract (156)
  2. Journal Article (142)
  3. Review (20)
  4. Book Section (17)
  5. Guidelines (5)
  6. Editorial (2)
Groups
  1. Molecular Imaging and Therapy Service (342)
  2. Radiology, Department of (342)
  3. GSK Faculty (145)
  4. Medical Physics (126)
  5. Department of Medicine (120)
  6. Molecular Pharmacology and Chemistry Program Faculty (103)

More Groups

People
  1. Steven Larson (99)
  2. Jorge Carrasquillo (77)
  3. Pat Zanzonico (57)
  4. Jason Lewis (52)
  5. Serge Lyashchenko (52)
  6. Kim Kramer (51)

More People

Years
  1. 2025 (5)
  2. 2024 (21)
  3. 2023 (31)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (12)

More Years

Publications
  1. Journal of Nuclear Medicine (66)
  2. Journal of Clinical Oncology (48)
  3. European Journal of Nuclear Medicine and Molecular Imaging (21)
  4. Pediatric Blood and Cancer (21)
  5. Neuro-Oncology (20)
  6. Blood (13)

More Publications

Publishers
  1. Society of Nuclear Medicine (66)
  2. Springer (49)
  3. American Society of Clinical Oncology (48)
  4. Elsevier Inc. (38)
  5. Oxford University Press (23)
  6. Wiley Periodicals, Inc (21)

More Publishers

Results (342)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quantifying intrathecal drug delivery utilizing programmable ventriculoperitoneal shunts
    Meeting Abstract

    McThenia, S.; Pandit-Taskar, N.; Grkovski, M.; Donzelli, M.; Diagana, S.; Greenfield, J.; Souweidane, M.; Kramer, K.
    Neuro-Oncology Advances (2021)

    Fulltext@MSK | Save
  • Dosimetry in clinical radiopharmaceutical therapy of cancer: Practicality versus perfection in current practice
    Review

    Pandit-Taskar, N.; Iravani, A.; Lee, D.; Jacene, H.; Pryma, D.; Hope, T.; Saboury, B.; Capala, J.; Wahl, R. L.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Tumor response to radiopharmaceutical therapies: The knowns and the unknowns
    Review

    Sgouros, G.; Dewaraja, Y. K.; Escorcia, F.; Graves, S. A.; Hope, T. A.; Iravani, A.; Pandit-Taskar, N.; Saboury, B.; James, S. S.; Zanzonico, P. B.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Low incidence rates of mucositis, febrile neutropenia or sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia with targeted delivery of anti-CD45 iodine ((131)I) apamistamab [Iomab-B]
    Meeting Abstract

    Natwa, M.; Passalaqua, S.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Mhlanga, J.; Wahl, R.; Avril, N.; more...
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Relationship of marrow radiation dose and timing of engraftment for targeted radioimmunotherapy with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] in patients with active relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Passalaqua, S.; Natwa, M.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Mhlanga, J.; Wahl, R.; Avril, N.; more...
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Phase 1 dose-escalation trial using convection-enhanced delivery of radiolabeled monoclonal antibody for diffuse intrinsic pontine glioma following external radiation therapy
    Meeting Abstract

    Souweidane, M. M.; Kramer, K.; Pandit-Taskar, N.; Haque, S.; Zanzonico, P.; Carrasquillo, J. A.; Lyashchenko, S. K.; Thakur, S. B.; Khakoo, Y.; Donzelli, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Imaging HER2-positive metastatic esophagogastric cancer with (89)Zr-trastuzumab PET and (18)F-FDG PET
    Meeting Abstract

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Janjigian, Y. Y.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II, nonrandomized open trial assessing pain efficacy with radium-223 in symptomatic metastatic castration-resistant prostate cancer
    Journal Article

    McHugh, D.; Tagawa, S.; Moryl, N.; Milowsky, M.; Heller, G.; Osborne, J.; Rathkopf, D.; Basch, E.; Pandit-Taskar, N.; Morris, M. J.
    Clinical Genitourinary Cancer (2021)

    Fulltext@MSK | Save